Experience with urethral stent explantation.

Purpose: We examined the timing, causes and results of the explantation of UroLume (American Medical Systems, Minnetonka, Minnesota) urethral stents.

Materials And Methods: The North American Study Group enrolled 465 patients in a trial of UroLume stent placement, including 69 (14.8% of the series) who required removal of a total of 73 stents (15.6% of stents) in 7 years. The time of explantation, reason for stent removal and local histological findings were determined from patient charts and reviewed in relation to the indication for stent placement.

Results: In patients treated for bladder outlet obstruction secondary to benign prostatic hyperplasia 23% of the stents were removed, as were 5% of those implanted in patients with bulbar urethral stricture and 22% of those in patients with detrusor-sphincter dyssynergia (see figure). Of the explantations 43.8% were done during year 1. Migration and/or inappropriate placement was the cause in 38.4% of cases. The most common stent site tissue finding was focal inflammation with a hyperplastic tissue response. Stent specific malignant changes were not observed. Stent removal was feasible with no sequelae. CONCLUSIONS When used appropriately, the UroLume endoprosthesis has a low incidence of failure. Stent removal is technically feasible and options are available for subsequent therapy. Local tissue reaction is minimal.